Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Perceptive’s dosimetry services deliver reliable and precise estimates of radiation absorbed doses, supporting new tracer and radioligand therapy development. Our experience includes multi-center clinical trials, pediatric studies, and preclinical and translational research with validated imaging workflows across multiple radionuclides and species.
Perceptive offers broad experience across a wide range of radionuclides, to support dosimetry for imaging and therapeutic applications:
11C
18F
64/67Cu
68Ga
89Zr
99mTc
111In
125I
131I
177Lu
203/212Pb
225Ac
223Ra
186Re
161Tb
Through advanced image segmentation, blood and urine data analysis, and model-based dose calculations, we deliver precise radiation estimates critical to safety and efficacy assessments. Our team utilizes validated models like OLINDA and custom dosimetry tools for organ- and tumor-specific calculations, supporting dose reporting for complex radiopharmaceutical programs.
Perceptive brings unmatched expertise to radioligand therapy (RLT) development, having supported over 80 clinical trials and hundreds of preclinical studies across diverse targets and indications. Our team provides comprehensive solutions, including radiochemistry, preclinical imaging, and early through late-phase clinical trial imaging expertise, and advanced quantitative imaging analysis. Having supported 85% of radiopharmaceutical companies, we are a key partner in innovating these therapies.
Through our collaborative approach and deep technical expertise, Perceptive partners with sponsors to navigate the complexities of radiopharmaceutical development, ensuring quality, compliance, and efficiency at every stage.
Phantoms play a vital role in dosimetry studies, serving as standardized tools for calibrating imaging systems and validating dose calculations. Perceptive offers phantoms that are engineered to replicate human anatomy and radiopharmaceutical distribution, ensuring high fidelity in data acquisition. These phantoms can be shipped directly to trial sites, enabling consistent calibration across multi-center studies and minimizing variability.
Leverage Perceptive’s unmatched expertise to advance your radioligand therapy studies. Contact our team to discuss how our dosimetry services can accelerate your success.
